Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Thrombin Clear all
Completed Phase 3 Interventional Results available

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

NCT00618098
View directory record Official record
Conditions
Reversal of Anticoagulant Treatment
Interventions
Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Nov 12, 2026, 4:48 AM EST
Active, not recruiting Phase 1 Interventional

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

NCT04057833
View directory record Official record
Conditions
Rotator Cuff Tears, Muscle Atrophy or Weakness, Tendon Rupture - Shoulder, Safety Issues
Interventions
E-CEL UVEC
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 3 Interventional

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

NCT00307515
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel)
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2009 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 3 Interventional Results available

Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis

NCT00491608
View directory record Official record
Conditions
Spinal Surgery, Vascular Surgery
Interventions
rThrombin
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Nov 12, 2026, 4:48 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

NCT01150812
View directory record Official record
Conditions
Thrombin Inhibition
Interventions
AZD8165
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Nov 12, 2026, 4:48 AM EST
Terminated Phase 2 Interventional Results available

Topical Raplixa for Surgical Bleeding in Children

NCT02117349
View directory record Official record
Conditions
Surgical Bleeding
Interventions
Raplixa, Gelfoam, Rescue treatment
Drug · Device
Lead sponsor
Mallinckrodt
Industry
Eligibility
Up to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 12, 2026, 4:48 AM EST
Completed Not applicable Interventional Results available

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

NCT03725098
View directory record Official record
Conditions
Cardiothoracic Surgery
Interventions
HEMOBLAST Bellows, FLOSEAL
Device
Lead sponsor
Biom'Up France SAS
Industry
Eligibility
Not listed
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Los Angeles, California • Honolulu, Hawaii • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 12, 2026, 4:48 AM EST
Active, not recruiting Phase 4 Interventional

Connective Tissue Matrix for Rotator Cuff Tendinopathy

NCT06160427
View directory record Official record
Conditions
Tendinopathy, Shoulder Pain, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis
Interventions
CTM Boost, PRP
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 3 Interventional

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

NCT00157131
View directory record Official record
Conditions
Deep Partial or Full Thickness Wounds
Interventions
Fibrin Sealant, ARTISS 4IU/ml VH SD, Staples
Biological · Other
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Up to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Nov 12, 2026, 4:48 AM EST
Recruiting Not applicable Interventional

Tract Closure in PCNL

NCT07668817
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Floseal, Surgicel, Surgiflo, Balloon Tamponade
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 2 Interventional Results available

The Fibrin Patch Soft Tissue Study

NCT00658723
View directory record Official record
Conditions
Hemostasis
Interventions
Fibrin Pad, SURGICEL™
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 2 Interventional Results available

The EVICEL® Gastrointestinal Study

NCT01589822
View directory record Official record
Conditions
Gastrointestinal Diseases
Interventions
EVICEL Fibrin Sealant
Biological
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
Irvine, California • Jacksonville, Florida • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study

NCT03255174
View directory record Official record
Conditions
Controlling Mild to Moderate Bleeding During Surgery
Interventions
EVARREST® Fibrin Sealant Patch
Biological
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
28 Days to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

NCT04660721
View directory record Official record
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Nov 12, 2026, 4:48 AM EST
Completed Not applicable Interventional Results available

GATT-Patch Versus TachoSil in Liver Surgery

NCT05385952
View directory record Official record
Conditions
Intraoperative Bleeding, Hemorrhage, Surgical, Liver Diseases
Interventions
GATT-Patch (currently named ETHIZIA), TachoSil
Device · Drug
Lead sponsor
GATT Technologies BV
Industry
Eligibility
22 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Los Angeles, California • St Louis, Missouri • Newark, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 4 Interventional Results available

Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants

NCT00859547
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
rThrombin, 1000 IU/mL
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Nov 12, 2026, 4:48 AM EST
Active, not recruiting No phase listed Observational

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

NCT06429787
View directory record Official record
Conditions
Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
Interventions
Balfaxar, Kcentra
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
3,574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 12, 2026, 4:48 AM EST
Completed No phase listed Observational

Treatment of Congenital Factor VII Deficiency

NCT01779921
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FVII Deficiency
Interventions
activated recombinant human factor VII, Fresh frozen plasma (Source unspecified), Plasma-derived FVII (LFB), Prothrombin Complex conc. (PCC), Plasma-derived FVII conc. (pdFVII Baxter), Plasma-derived FVII conc. (pdFVII PFL)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 3 Interventional Results available

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

NCT05523297
View directory record Official record
Conditions
Bleeding Cardiac Surgery Patients
Interventions
Octaplex, Frozen Plasma Product, Human
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Nov 12, 2026, 4:48 AM EST
Completed Phase 4 Interventional Results available

Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis

NCT00813904
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
rThrombin, 1000 IU/mL
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tuscon, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Nov 12, 2026, 4:48 AM EST